Symbols / TEVA $30.09 +2.14%
TEVA Chart
About
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 35.04B |
| Enterprise Value | 48.28B | Income | 1.41B | Sales | 17.26B |
| Book/sh | 6.88 | Cash/sh | 3.09 | Dividend Yield | — |
| Payout | 0.00% | Employees | 31173 | IPO | — |
| P/E | 24.87 | Forward P/E | 9.70 | PEG | — |
| P/S | 2.03 | P/B | 4.37 | P/C | — |
| EV/EBITDA | 9.74 | EV/Sales | 2.80 | Quick Ratio | 0.54 |
| Current Ratio | 1.04 | Debt/Eq | 217.72 | LT Debt/Eq | — |
| EPS (ttm) | 1.21 | EPS next Y | 3.10 | EPS Growth | — |
| Revenue Growth | 11.40% | Earnings | 2026-05-06 | ROA | 6.17% |
| ROE | 20.79% | ROIC | — | Gross Margin | 51.79% |
| Oper. Margin | 27.28% | Profit Margin | 8.17% | Shs Outstand | 1.16B |
| Shs Float | 1.07B | Short Float | 2.81% | Short Ratio | 3.37 |
| Short Interest | — | 52W High | 37.35 | 52W Low | 12.47 |
| Beta | 0.72 | Avg Volume | 9.20M | Volume | 9.10M |
| Target Price | $38.14 | Recom | Strong_buy | Prev Close | $29.46 |
| Price | $30.09 | Change | 2.14% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$38.14
Mean price target
2. Current target
$30.09
Latest analyst target
3. DCF / Fair value
$31.40
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$30.09
Low
$28.00
High
$45.00
Mean
$38.14
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-04 | reit | Piper Sandler | Overweight → Overweight | $41 |
| 2026-02-18 | main | Truist Securities | Buy → Buy | $42 |
| 2026-02-09 | main | Goldman Sachs | Buy → Buy | $45 |
| 2026-01-30 | main | Barclays | Overweight → Overweight | $38 |
| 2026-01-29 | main | Scotiabank | Sector Outperform → Sector Outperform | $40 |
| 2026-01-29 | main | Truist Securities | Buy → Buy | $38 |
| 2026-01-06 | main | Jefferies | Buy → Buy | $40 |
| 2025-12-22 | main | Piper Sandler | Overweight → Overweight | $40 |
| 2025-12-19 | main | Goldman Sachs | Buy → Buy | $35 |
| 2025-12-16 | main | JP Morgan | Overweight → Overweight | $35 |
| 2025-12-09 | main | B of A Securities | Buy → Buy | $32 |
| 2025-12-09 | init | Barclays | — → Overweight | $35 |
| 2025-12-08 | main | Goldman Sachs | Buy → Buy | $31 |
| 2025-12-05 | init | Scotiabank | — → Sector Outperform | $35 |
| 2025-11-06 | main | JP Morgan | Overweight → Overweight | $28 |
| 2025-10-03 | main | JP Morgan | Overweight → Overweight | $26 |
| 2025-09-24 | main | UBS | Buy → Buy | $26 |
| 2025-06-26 | main | UBS | Buy → Buy | $23 |
| 2025-06-06 | init | Goldman Sachs | — → Buy | $24 |
| 2025-05-28 | init | Truist Securities | — → Buy | $25 |
- Piper Sandler reiterates Teva stock rating on IBD treatment outlook - Investing.com Mon, 16 Mar 2026 13
- Is Teva Pharmaceutical Industries (TEVA) A Good Stock To Buy Now? - Yahoo Finance Sun, 15 Mar 2026 21
- Teva Stock: CEO Emphasizes The 'Remarkable Story' Behind Its Guidance - Investor's Business Daily Wed, 28 Jan 2026 08
- Teva CEO cashes in $30 million in shares in two weeks - CTech Sun, 08 Mar 2026 08
- Militia Capital Partners LP Invests $1.82 Million in Teva Pharmaceutical Industries Ltd. $TEVA - MarketBeat ue, 17 Mar 2026 12
- A Look At Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Branded Drugs Pass $1b Quarterly Revenue - simplywall.st ue, 17 Mar 2026 02
- Teva Stock Is Jumping. Why Investors Are So Optimistic on the Drugmaker. - Barron's Mon, 12 Jan 2026 08
- Dow, S&P 500 Set to Snap 4-Day Skid as Oil, Bond Yields Cool - Schaeffer's Investment Research Mon, 16 Mar 2026 15
- Here's Why I Won't Touch Teva Pharmaceutical With a 10‑Foot Pole - The Motley Fool Fri, 27 Feb 2026 08
- Is It Too Late To Reassess Teva Pharmaceutical Industries (TEVA) After Its 75% One Year Rally? - Yahoo Finance Sun, 15 Mar 2026 19
- Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Private Management Group Inc. - MarketBeat Sat, 14 Mar 2026 09
- Truist Boosts Teva (TEVA) Stock Target Amid Pipeline Growth Opportunities - Yahoo Finance Fri, 20 Feb 2026 08
- Teva Pharmaceutical Industries Ltd. $TEVA Shares Bought by Menora Mivtachim Holdings LTD. - MarketBeat Fri, 13 Mar 2026 10
- Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Swiss National Bank - MarketBeat hu, 12 Mar 2026 12
- Farallon Capital Management LLC Takes $100.94 Million Position in Teva Pharmaceutical Industries Ltd. $TEVA - MarketBeat Mon, 16 Mar 2026 10
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 42452 | — | — | FRANCIS RICHARD D | Chief Executive Officer | — | 2026-03-05 00:00:00 | D | nan |
| 1 | 15723 | — | — | SABAG MARK | Officer | — | 2026-03-05 00:00:00 | D | nan |
| 2 | 19916 | — | — | KALIF ELIYAHU SHARON | Chief Financial Officer | — | 2026-03-05 00:00:00 | D | nan |
| 3 | 19654 | — | — | HUGHES ERIC A | Officer | — | 2026-03-05 00:00:00 | D | nan |
| 4 | 17819 | — | — | FOX CHRISTINE | Officer | — | 2026-03-05 00:00:00 | D | nan |
| 5 | 17295 | — | — | SHIELDS MATTHEW | Officer | — | 2026-03-05 00:00:00 | D | nan |
| 6 | 3580 | — | — | SAVAGE BRIAN | Officer | — | 2026-03-05 00:00:00 | D | nan |
| 7 | 9533 | — | Sale at price 31.67 per share. | HUGHES ERIC A | Officer | — | 2026-03-05 00:00:00 | D | 301895.0 |
| 8 | 7924 | — | Sale at price 31.67 per share. | FOX CHRISTINE | Officer | — | 2026-03-05 00:00:00 | D | 250940.0 |
| 9 | 17295 | — | Sale at price 31.67 per share. | SHIELDS MATTHEW | Officer | — | 2026-03-05 00:00:00 | D | 547705.0 |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -400.89M | -829.61M | -27.14M | -966.60M |
| TaxRateForCalcs | 0.23 | 0.23 | 0.01 | 0.20 |
| NormalizedEBITDA | 4.88B | 4.38B | 4.27B | 3.91B |
| TotalUnusualItems | -1.74B | -3.61B | -2.71B | -4.83B |
| TotalUnusualItemsExcludingGoodwill | -1.74B | -3.61B | -2.71B | -4.83B |
| NetIncomeFromContinuingOperationNetMinorityInterest | 1.41B | -1.64B | -559.00M | -2.45B |
| ReconciledDepreciation | 1.00B | 1.06B | 1.15B | 1.31B |
| ReconciledCostOfRevenue | 8.32B | 8.48B | 8.20B | 7.95B |
| EBITDA | 3.14B | 777.00M | 1.56B | -925.00M |
| EBIT | 2.14B | -282.00M | 405.00M | -2.23B |
| NetInterestIncome | -985.00M | -1.05B | -1.09B | -991.00M |
| InterestExpense | 916.00M | 1.00B | 1.03B | 930.00M |
| NormalizedIncome | 2.75B | 1.14B | 2.13B | 1.42B |
| NetIncomeFromContinuingAndDiscontinuedOperation | 1.41B | -1.64B | -559.00M | -2.45B |
| TotalExpenses | 13.31B | 13.18B | 12.65B | 12.23B |
| TotalOperatingIncomeAsReported | 2.16B | -303.00M | 433.00M | -2.20B |
| DilutedAverageShares | 1.16B | 1.13B | 1.12B | 1.11B |
| BasicAverageShares | 1.15B | 1.13B | 1.12B | 1.11B |
| DilutedEPS | 1.21 | -1.45 | -0.50 | -2.12 |
| BasicEPS | 1.23 | -1.45 | -0.50 | -2.12 |
| DilutedNIAvailtoComStockholders | 1.41B | -1.64B | -559.00M | -2.45B |
| NetIncomeCommonStockholders | 1.41B | -1.64B | -559.00M | -2.45B |
| NetIncome | 1.41B | -1.64B | -559.00M | -2.45B |
| MinorityInterests | -7.00M | 320.00M | 56.00M | 53.00M |
| NetIncomeIncludingNoncontrollingInterests | 1.42B | -1.96B | -615.00M | -2.50B |
| NetIncomeContinuousOperations | 1.42B | -1.96B | -615.00M | -2.50B |
| EarningsFromEquityInterestNetOfTax | 15.00M | 1.00M | 2.00M | 21.00M |
| TaxProvision | -180.00M | 676.00M | -7.00M | -643.00M |
| PretaxIncome | 1.22B | -1.28B | -624.00M | -3.16B |
| OtherIncomeExpense | -1.74B | -3.60B | -2.72B | -4.86B |
| OtherNonOperatingIncomeExpenses | 1.00M | 10.00M | -9.00M | -26.00M |
| SpecialIncomeCharges | -1.79B | -3.68B | -2.75B | -4.86B |
| GainOnSaleOfPPE | 2.00M | 2.00M | 25.00M | 18.00M |
| GainOnSaleOfBusiness | -22.00M | 15.00M | 3.00M | 46.00M |
| OtherSpecialCharges | 467.00M | 761.00M | 1.04B | 2.07B |
| ImpairmentOfCapitalAssets | 1.03B | 2.56B | 1.08B | 2.45B |
| RestructuringAndMergernAcquisition | 279.00M | 377.00M | 659.00M | 407.00M |
| GainOnSaleOfSecurity | 51.00M | 69.00M | 38.00M | 26.00M |
| NetNonOperatingInterestIncomeExpense | -985.00M | -1.05B | -1.09B | -991.00M |
| TotalOtherFinanceCost | 69.00M | 48.00M | 66.00M | 61.00M |
| InterestExpenseNonOperating | 916.00M | 1.00B | 1.03B | 930.00M |
| OperatingIncome | 3.95B | 3.36B | 3.19B | 2.69B |
| OperatingExpense | 4.99B | 4.70B | 4.45B | 4.28B |
| ResearchAndDevelopment | 1.01B | 998.00M | 953.00M | 838.00M |
| SellingGeneralAndAdministration | 3.97B | 3.70B | 3.50B | 3.44B |
| SellingAndMarketingExpense | 2.69B | 2.54B | 2.34B | 2.27B |
| GeneralAndAdministrativeExpense | 1.29B | 1.16B | 1.16B | 1.18B |
| OtherGandA | 1.29B | 1.16B | 1.16B | 1.18B |
| GrossProfit | 8.94B | 8.06B | 7.64B | 6.97B |
| CostOfRevenue | 8.32B | 8.48B | 8.20B | 7.95B |
| TotalRevenue | 17.26B | 16.54B | 15.85B | 14.93B |
| OperatingRevenue | 16.83B | 15.80B | 15.28B | 14.50B |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 106.56M | 107.00M | 106.00M | 106.00M |
| OrdinarySharesNumber | 1.15B | 1.13B | 1.12B | 1.11B |
| ShareIssued | 1.26B | 1.24B | 1.23B | 1.22B |
| NetDebt | 13.25B | 14.48B | 16.61B | 18.41B |
| TotalDebt | 17.09B | 18.08B | 20.15B | 21.56B |
| TangibleBookValue | -11.87B | -14.19B | -15.06B | -16.10B |
| InvestedCapital | 24.72B | 23.16B | 27.34B | 29.02B |
| WorkingCapital | 490.00M | -244.00M | 238.00M | 582.00M |
| NetTangibleAssets | -11.87B | -14.19B | -15.06B | -16.10B |
| CapitalLeaseObligations | 288.00M | 296.00M | 320.00M | 349.00M |
| CommonStockEquity | 7.91B | 5.37B | 7.51B | 7.80B |
| TotalCapitalization | 22.90B | 21.38B | 25.67B | 26.91B |
| TotalEquityGrossMinorityInterest | 7.91B | 5.72B | 8.13B | 8.60B |
| MinorityInterest | 4.00M | 347.00M | 620.00M | 794.00M |
| StockholdersEquity | 7.91B | 5.37B | 7.51B | 7.80B |
| OtherEquityInterest | 1.00M | |||
| GainsLossesNotAffectingRetainedEarnings | -2.39B | -3.15B | -2.70B | -2.84B |
| OtherEquityAdjustments | -2.39B | -3.15B | -2.70B | -2.84B |
| TreasuryStock | 4.13B | 4.13B | 4.13B | 4.13B |
| RetainedEarnings | -13.76B | -15.17B | -13.53B | -12.97B |
| AdditionalPaidInCapital | 28.13B | 27.76B | 27.81B | 27.69B |
| CapitalStock | 58.00M | 58.00M | 57.00M | 57.00M |
| CommonStock | 58.00M | 58.00M | 57.00M | 57.00M |
| TotalLiabilitiesNetMinorityInterest | 32.83B | 33.61B | 35.35B | 35.41B |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 19.38B | 20.81B | 23.11B | 23.94B |
| OtherNonCurrentLiabilities | 3.81B | 4.03B | 4.02B | 3.94B |
| TradeandOtherPayablesNonCurrent | 3.85B | 2.58B | ||
| NonCurrentDeferredLiabilities | 296.00M | 483.00M | 606.00M | 548.00M |
| NonCurrentDeferredTaxesLiabilities | 296.00M | 483.00M | 606.00M | 548.00M |
| LongTermDebtAndCapitalLeaseObligation | 15.27B | 16.30B | 18.48B | 19.45B |
| LongTermCapitalLeaseObligation | 288.00M | 296.00M | 320.00M | 349.00M |
| LongTermDebt | 14.99B | 16.00B | 18.16B | 19.10B |
| CurrentLiabilities | 13.46B | 12.80B | 12.25B | 11.47B |
| OtherCurrentLiabilities | 1.54B | 1.72B | 1.06B | 1.01B |
| CurrentDebtAndCapitalLeaseObligation | 1.82B | 1.78B | 1.67B | 2.11B |
| CurrentDebt | 1.82B | 1.78B | 1.67B | 2.11B |
| OtherCurrentBorrowings | 1.82B | 1.78B | 1.67B | 2.11B |
| PensionandOtherPostRetirementBenefitPlansCurrent | 739.00M | 624.00M | 611.00M | 566.00M |
| CurrentProvisions | 4.14B | 3.68B | 3.54B | 3.75B |
| PayablesAndAccruedExpenses | 5.22B | 5.00B | 5.37B | 4.04B |
| CurrentAccruedExpenses | 2.69B | 2.79B | 2.77B | 2.15B |
| Payables | 2.53B | 2.20B | 2.60B | 1.89B |
| AccountsPayable | 2.53B | 2.20B | 2.60B | 1.89B |
| TotalAssets | 40.75B | 39.33B | 43.48B | 44.01B |
| TotalNonCurrentAssets | 26.80B | 26.77B | 30.99B | 31.96B |
| OtherNonCurrentAssets | 405.00M | 462.00M | 470.00M | 441.00M |
| NonCurrentDeferredAssets | 2.19B | 1.80B | 1.81B | 1.46B |
| NonCurrentDeferredTaxesAssets | 2.19B | 1.80B | 1.81B | 1.46B |
| GoodwillAndOtherIntangibleAssets | 19.78B | 19.57B | 22.56B | 23.90B |
| OtherIntangibleAssets | 3.78B | 4.42B | 5.39B | 6.27B |
| Goodwill | 16.00B | 15.15B | 17.18B | 17.63B |
| NetPPE | 4.42B | 4.95B | 6.15B | 6.16B |
| AccumulatedDepreciation | -4.73B | -4.41B | -5.64B | -5.52B |
| GrossPPE | 9.15B | 9.36B | 11.78B | 11.68B |
| ConstructionInProgress | 377.00M | 1.33B | 1.43B | 1.20B |
| OtherProperties | 345.00M | 367.00M | 397.00M | 419.00M |
| MachineryFurnitureEquipment | 5.85B | 5.48B | 7.23B | 7.35B |
| BuildingsAndImprovements | 2.33B | 1.97B | 2.49B | 2.46B |
| LandAndImprovements | 258.00M | 213.00M | 246.00M | 246.00M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 13.95B | 12.55B | 12.48B | 12.05B |
| OtherCurrentAssets | 538.00M | 409.00M | 505.00M | 549.00M |
| AssetsHeldForSaleCurrent | 1.84B | 1.77B | 70.00M | 10.00M |
| PrepaidAssets | 1.12B | 1.01B | 1.25B | 1.16B |
| Inventory | 3.18B | 3.01B | 4.02B | 3.83B |
| OtherInventories | 1.00M | -1.00M | ||
| FinishedGoods | 1.90B | 1.78B | 2.35B | 1.99B |
| WorkInProcess | 364.00M | 353.00M | 500.00M | 555.00M |
| RawMaterials | 911.00M | 870.00M | 1.18B | 1.29B |
| Receivables | 3.71B | 3.06B | 3.41B | 3.70B |
| AccountsReceivable | 3.71B | 3.06B | 3.41B | 3.70B |
| AllowanceForDoubtfulAccountsReceivable | -81.00M | -78.00M | -95.00M | -91.00M |
| GrossAccountsReceivable | 3.79B | 3.14B | 3.50B | 3.79B |
| CashCashEquivalentsAndShortTermInvestments | 3.56B | 3.30B | 3.23B | 2.80B |
| CashAndCashEquivalents | 3.56B | 3.30B | 3.23B | 2.80B |
| CashEquivalents | 2.68B | 2.00B | 1.70B | 1.22B |
| CashFinancial | 878.00M | 1.29B | 1.52B | 1.58B |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 1.15B | 749.00M | 842.00M | 1.04B |
| RepaymentOfDebt | -4.11B | -1.64B | -4.85B | -1.37B |
| IssuanceOfDebt | 2.30B | 0.00 | 3.15B | 0.00 |
| CapitalExpenditure | -501.00M | -498.00M | -526.00M | -548.00M |
| InterestPaidSupplementalData | 950.00M | 1.00B | 1.08B | 948.00M |
| IncomeTaxPaidSupplementalData | 471.00M | 298.00M | 543.00M | 495.00M |
| EndCashPosition | 3.56B | 3.30B | 3.23B | 2.83B |
| BeginningCashPosition | 3.30B | 3.23B | 2.83B | 2.20B |
| EffectOfExchangeRateChanges | 21.00M | -174.00M | -30.00M | -123.00M |
| ChangesInCash | 235.00M | 247.00M | 423.00M | 759.00M |
| FinancingCashFlow | -2.15B | -1.79B | -1.91B | -1.49B |
| CashFlowFromContinuingFinancingActivities | -2.15B | -1.79B | -1.91B | -1.49B |
| NetOtherFinancingCharges | -337.00M | -150.00M | -212.00M | -118.00M |
| NetIssuancePaymentsOfDebt | -1.81B | -1.64B | -1.70B | -1.37B |
| NetShortTermDebtIssuance | 0.00 | 0.00 | 0.00 | 0.00 |
| ShortTermDebtPayments | 0.00 | 0.00 | -700.00M | 0.00 |
| ShortTermDebtIssuance | 0.00 | 0.00 | 700.00M | 0.00 |
| NetLongTermDebtIssuance | -1.81B | -1.64B | -1.70B | -1.37B |
| LongTermDebtPayments | -4.11B | -1.64B | -4.15B | -1.37B |
| LongTermDebtIssuance | 2.30B | 0.00 | 2.45B | 0.00 |
| InvestingCashFlow | 737.00M | 792.00M | 968.00M | 656.00M |
| CashFlowFromContinuingInvestingActivities | 737.00M | 792.00M | 968.00M | 656.00M |
| NetOtherInvestingChanges | 5.00M | 2.00M | -5.00M | 1.00M |
| InterestReceivedCFI | 1.21B | 1.29B | 1.48B | 1.14B |
| NetInvestmentPurchaseAndSale | -15.00M | -31.00M | -46.00M | 3.00M |
| SaleOfInvestment | 42.00M | 40.00M | 0.00 | 4.00M |
| PurchaseOfInvestment | -57.00M | -71.00M | -46.00M | -1.00M |
| NetBusinessPurchaseAndSale | 34.00M | 28.00M | 68.00M | 61.00M |
| SaleOfBusiness | 34.00M | 43.00M | 68.00M | 68.00M |
| PurchaseOfBusiness | 0.00 | -15.00M | 0.00 | -7.00M |
| NetPPEPurchaseAndSale | -501.00M | -498.00M | -526.00M | -548.00M |
| SaleOfPPE | 311.00M | |||
| PurchaseOfPPE | -501.00M | -498.00M | -526.00M | -548.00M |
| OperatingCashFlow | 1.65B | 1.25B | 1.37B | 1.59B |
| CashFlowFromContinuingOperatingActivities | 1.65B | 1.25B | 1.37B | 1.59B |
| ChangeInWorkingCapital | -1.37B | -435.00M | -72.00M | 1.35B |
| ChangeInOtherCurrentAssets | -1.33B | -1.10B | -1.52B | -828.00M |
| ChangeInPayablesAndAccruedExpense | -15.00M | 258.00M | 1.59B | 2.01B |
| ChangeInPayable | -15.00M | 258.00M | 1.59B | 2.01B |
| ChangeInAccountPayable | -15.00M | 258.00M | 1.59B | 2.01B |
| ChangeInInventory | 152.00M | 166.00M | -147.00M | -163.00M |
| ChangeInReceivables | -173.00M | 245.00M | 12.00M | 334.00M |
| ChangesInAccountReceivables | -173.00M | 245.00M | 12.00M | 334.00M |
| OtherNonCashItems | 81.00M | 560.00M | 61.00M | -91.00M |
| StockBasedCompensation | 157.00M | 123.00M | 121.00M | 124.00M |
| AssetImpairmentCharge | 1.03B | 2.56B | 1.08B | 2.45B |
| DeferredTax | -671.00M | -634.00M | -317.00M | -1.06B |
| DeferredIncomeTax | -671.00M | -634.00M | -317.00M | -1.06B |
| DepreciationAmortizationDepletion | 1.00B | 1.06B | 1.15B | 1.31B |
| DepreciationAndAmortization | 1.00B | 1.06B | 1.15B | 1.31B |
| AmortizationCashFlow | 581.00M | 588.00M | 616.00M | 732.00M |
| AmortizationOfIntangibles | 581.00M | 588.00M | 616.00M | 732.00M |
| Depreciation | 421.00M | 471.00M | 537.00M | 576.00M |
| OperatingGainsLosses | -22.00M | -41.00M | 10.00M | 104.00M |
| GainLossOnInvestmentSecurities | -41.00M | 10.00M | 104.00M | |
| GainLossOnSaleOfPPE | 10.00M | 104.00M | ||
| GainLossOnSaleOfBusiness | 0.00 | -22.00M | -41.00M | 10.00M |
| NetIncomeFromContinuingOperations | 1.42B | -1.96B | -615.00M | -2.50B |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for TEVA
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|